JoAnn Lim

529 total citations
21 papers, 325 citations indexed

About

JoAnn Lim is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, JoAnn Lim has authored 21 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Epidemiology. Recurrent topics in JoAnn Lim's work include Antifungal resistance and susceptibility (4 papers), Neutropenia and Cancer Infections (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). JoAnn Lim is often cited by papers focused on Antifungal resistance and susceptibility (4 papers), Neutropenia and Cancer Infections (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). JoAnn Lim collaborates with scholars based in United States, Netherlands and Brazil. JoAnn Lim's co-authors include Elihu H. Estey, Hagop M. Kantarjian, Jörge E. Cortes, Sherry Pierce, Issam Raad, Rhonda Fleming, Kenneth V. I. Rolston, Rola Husni, Siqing Fu and David S. Hong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

JoAnn Lim

20 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JoAnn Lim United States 9 134 119 108 65 52 21 325
B. J. Dezube United States 9 103 0.8× 213 1.8× 114 1.1× 15 0.2× 42 0.8× 20 420
Bozong Tang China 11 77 0.6× 89 0.7× 107 1.0× 33 0.5× 133 2.6× 11 399
Daniela Sporrer Germany 6 129 1.0× 141 1.2× 92 0.9× 67 1.0× 257 4.9× 8 472
Hitoshi Yonezawa Japan 12 48 0.4× 135 1.1× 25 0.2× 166 2.6× 96 1.8× 24 379
Dario Lipari Italy 5 51 0.4× 50 0.4× 67 0.6× 83 1.3× 52 1.0× 9 258
Kimitaka Akaike Japan 9 76 0.6× 187 1.6× 51 0.5× 123 1.9× 194 3.7× 26 438
Kazuya Okushin Japan 9 21 0.2× 71 0.6× 215 2.0× 22 0.3× 86 1.7× 28 373
Marc Diedisheim France 12 56 0.4× 29 0.2× 58 0.5× 15 0.2× 85 1.6× 22 507

Countries citing papers authored by JoAnn Lim

Since Specialization
Citations

This map shows the geographic impact of JoAnn Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JoAnn Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JoAnn Lim more than expected).

Fields of papers citing papers by JoAnn Lim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JoAnn Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JoAnn Lim. The network helps show where JoAnn Lim may publish in the future.

Co-authorship network of co-authors of JoAnn Lim

This figure shows the co-authorship network connecting the top 25 collaborators of JoAnn Lim. A scholar is included among the top collaborators of JoAnn Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JoAnn Lim. JoAnn Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gouda, Mohamed A., Matthew J. Reilley, Amadeo B. Biter, et al.. (2025). Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. PubMed. 8(2). 89–98. 1 indexed citations
2.
3.
Reilley, Matthew J., Amadeo B. Biter, JoAnn Lim, et al.. (2023). Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.. Journal of Clinical Oncology. 41(16_suppl). 2564–2564. 2 indexed citations
4.
DiPeri, Timothy P., Daniel D. Karp, Siqing Fu, et al.. (2022). Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. SHILAP Revista de lepidopterología. 5(1). 26–30.
5.
Schilperoort, Maaike, Nathalie Bravenboer, JoAnn Lim, et al.. (2019). Circadian disruption by shifting the light‐dark cycle negatively affects bone health in mice. The FASEB Journal. 34(1). 1052–1064. 33 indexed citations
6.
Ruiter, Godard C. W. de, JoAnn Lim, Bregje J.W. Thomassen, & Sjoerd G. van Duinen. (2018). Histopathologic changes inside the lateral femoral cutaneous nerve obtained from patients with persistent symptoms of meralgia paresthetica. Acta Neurochirurgica. 161(2). 263–269. 7 indexed citations
7.
Kato, Shumei, Denis L. Jardim, Faye M. Johnson, et al.. (2017). Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs. 36(3). 416–423. 17 indexed citations
8.
Reilley, Matthew J., Ann M. Bailey, Vivek Subbiah, et al.. (2017). Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer. 5(1). 35–35. 49 indexed citations
9.
Reilley, Matthew J., Ann M. Bailey, Vivek Subbiah, et al.. (2016). Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.. Journal of Clinical Oncology. 34(15_suppl). 3054–3054. 6 indexed citations
10.
Said, Rabih, Razelle Kurzrock, Aung Naing, et al.. (2015). Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs. 33(4). 911–920. 4 indexed citations
11.
Lim, JoAnn, Bettzy Stephen, Filip Jankú, et al.. (2015). Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs. 33(3). 700–709. 11 indexed citations
12.
Lim, JoAnn, Bettzy Stephen, Filip Jankú, et al.. (2015). Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.. Journal of Clinical Oncology. 33(15_suppl). 2588–2588. 2 indexed citations
13.
Tsimberidou, Apostolia M., Mark B. Leick, JoAnn Lim, et al.. (2012). Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemotherapy and Pharmacology. 71(2). 389–397. 13 indexed citations
14.
Camacho, Luis H., JoAnn Lim, David S. Hong, et al.. (2010). Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer. 9(5). 311–314. 8 indexed citations
15.
16.
Mattiuzzi, Gloria, Hagop M. Kantarjian, Stefan Faderl, et al.. (2004). Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 100(3). 581–589. 30 indexed citations
17.
18.
Mattiuzzi, Gloria, Gladys Alvarado, Hagop M. Kantarjian, et al.. (2004). Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).. Blood. 104(11). 885–885. 5 indexed citations
19.
Giles, Francis J., et al.. (2003). Intravenous Corticosteroids to Reduce Gemtuzumab Ozogamicin Infusion Reactions. Annals of Pharmacotherapy. 37(9). 1182–1185. 14 indexed citations
20.
Fleming, Rhonda, Hagop M. Kantarjian, Rola Husni, et al.. (2001). Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with Leukemia. Leukemia & lymphoma. 40(5-6). 511–520. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. J. Dezube Breakdown of academic impact, for papers by Bozong Tang Breakdown of academic impact, for papers by Daniela Sporrer Breakdown of academic impact, for papers by Hitoshi Yonezawa Breakdown of academic impact, for papers by Dario Lipari Breakdown of academic impact, for papers by Kimitaka Akaike Breakdown of academic impact, for papers by Kazuya Okushin Breakdown of academic impact, for papers by Marc Diedisheim
Rankless by CCL
2026